ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney

Related Keywords

Austria ,United Kingdom ,Taiwan ,France ,United States ,Singapore ,Canada ,Ukraine ,Belgium ,Spain ,Americans ,America ,Tim Bertram ,Asia Pacific ,Selina Husain Robert Flamm ,Stefan Klotter ,Lee Roth ,Dburns Mcclellan ,Glenn Schulman ,Joseph Stavas ,Clinical Development Updates ,Drug Administration ,European Medicines Agency ,Capital Suvretta Holding Corp ,Health Canada ,Nasdaq ,Head Of Global Clinical Development ,Company Class ,Exchange Commission ,Healthcare Products Regulatory Agency ,Society Of Interventional Radiology ,Prokidney Corp ,Chief Executive Officer ,Global Clinical Development ,Interventional Procedures ,Corporate Highlights ,Clinical Development ,United Kingdom Medicines ,Taiwan Food ,Latin America ,Interventional Radiology ,Marketing Authorization ,Social Capital Suvretta Holding ,Loss Before Noncontrolling Interest ,Renal Autologous Cell Therapy ,Regenerative Medicine Advanced Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Robert Flamm ,Months Ended December ,Ended December ,Business Combination ,Diese Aktien ,Profi Stefan Klotter ,Prokidney ,Reports ,Fourth ,Quarter ,Financial ,Results ,Ecent ,Corporate ,Highlights ,